Analysis of published criteria for clinically inactive disease in a large juvenile dermatomyositis cohort shows that skin disease is underestimated

Arthritis and Rheumatology

Volumn 67, Issue 9, 2015, Pages 2495-2502

  Almeida, Beverley ^a   Campanilho Marques, Raquel ^a   Arnold, Katie ^a   Pilkington, Clarissa A ^b   Wedderburn, Lucy R ^a,b   Nistala, Kiran ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; JUVENILE DERMATOMYOSITIS; PRIORITY JOURNAL; ADOLESCENT; BLOOD; CALCINOSIS; CHILD; COHORT ANALYSIS; COMPLICATION; DERMATOMYOSITIS; EXANTHEMA; FEMALE; HUMAN; LONGITUDINAL STUDY; MALE; MUSCLE STRENGTH; PROSPECTIVE STUDY; SKIN DISEASES; SKIN ULCER; UNITED KINGDOM;

CREATINE KINASE;

ADOLESCENT; CALCINOSIS; CHILD; COHORT STUDIES; CREATINE KINASE; DERMATOMYOSITIS; EXANTHEMA; FEMALE; GREAT BRITAIN; HUMANS; LONGITUDINAL STUDIES; MALE; MUSCLE STRENGTH; PROSPECTIVE STUDIES; SKIN DISEASES; SKIN ULCER;

EID: 84940106553     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39200     Document Type: Article

References (17)

1. Symmons DP, Sills JA, Davis SM., The incidence of juvenile dermatomyositis: results from a nation-wide study. Br J Rheumatol 1995; 34: 732-6.
2. Mendez EP, Lipton R, Ramsey-Goldman R, Roettcher P, Bowyer S, Dyer A, et al, for the NIAMS Juvenile DM Registry Physician Referral Group. US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum 2003; 49: 300-5.
3. Rider LG, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N, et al., Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res (Hoboken) 2011; 63 Suppl 11: S118-57.
4. Lazarevic D, Pistorio A, Palmisani E, Miettunen P, Ravelli A, Pilkington C, et al., The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. Ann Rheum Dis 2013; 72: 686-93.
5. Lovell DJ, Lindsley CB, Rennebohm RM, Ballinger SH, Bowyer SL, Giannini EH, et al, in cooperation with the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. Arthritis Rheum 1999; 42: 2213-9.
6. Rider LG, Koziol D, Giannini EH, Jain MS, Smith MR, Whitney-Mahoney K, et al., Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken) 2010; 62: 465-72.
7. Bowyer SL, Blane CE, Sullivan DB, Cassidy JT., Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr 1983; 103: 882-8.
8. Pachman LM, Hayford JR, Chung A, Daugherty CA, Pallansch MA, Fink CW, et al., Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. J Rheumatol 1998; 25: 1198-204.
9. Huber AM, Lang B, LeBlanc CM, Birdi N, Bolaria RK, Malleson P, et al., Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 2000; 43: 541-9.
10. Mathiesen P, Hegaard H, Herlin T, Zak M, Pedersen FK, Nielsen S., Long-term outcome in patients with juvenile dermatomyositis: a cross-sectional follow-up study. Scand J Rheumatol 2012; 41: 50-8.
11. Martin N, Krol P, Smith S, Murray K, Pilkington CA, Davidson JE, et al, on behalf of the Juvenile Dermatomyositis Research Group. A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies: 10 years' experience; the Juvenile Dermatomyositis National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies [published erratum appears in Rheumatology (Oxford) 2011;50:635]. Rheumatology (Oxford) 2011; 50: 137-45.
12. Bohan A, Peter JB., Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344-7.
13. Bohan A, Peter JB., Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292: 403-7.
14. Bode RK, Klein-Gitelman MS, Miller ML, Lechman TS, Pachman LM., Disease Activity Score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Rheum 2003; 49: 7-15.
15. Oddis CV, Rider LG, Reed AM, Ruperto N, Brunner HI, Koneru B, et al, for the International Myositis Assessment and Clinical Studies Group. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 2005; 52: 2607-15.
16. Sanner H, Sjaastad I, Flato B., Disease activity and prognostic factors in juvenile dermatomyositis: a long-term follow-up study applying the Paediatric Rheumatology International Trials Organization criteria for inactive disease and the myositis disease activity assessment tool. Rheumatology (Oxford) 2014; 53: 1578-85.
17. Isenberg DA, Allen E, Farewell V, Ehrenstein MR, Hanna MG, Lundberg IE, et al., International consensus outcome measures for patients with idiopathic inflammatory myopathies: development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 2004; 43: 49-54.